Pardo I, Maezato A, Callado G, Gutfreund M, Hsieh M, Lin V
Antimicrob Steward Healthc Epidemiol. 2024; 4(1):e152.
PMID: 39346662
PMC: 11427957.
DOI: 10.1017/ash.2024.369.
Martin-Sanchez E, Tamariz-Amador L, Guerrero C, Zherniakova A, Zabaleta A, Maia C
Blood Cancer J. 2024; 14(1):111.
PMID: 38987557
PMC: 11237013.
DOI: 10.1038/s41408-024-01089-5.
Hua T, Fan R, Fan Y, Chen F
Hum Vaccin Immunother. 2024; 20(1):2357424.
PMID: 38785118
PMC: 11135846.
DOI: 10.1080/21645515.2024.2357424.
Dukes C, Potez M, Lancet J, Kuter B, Whiting J, Mo Q
Vaccines (Basel). 2024; 12(1).
PMID: 38250826
PMC: 10818923.
DOI: 10.3390/vaccines12010013.
Hall V, Nguyen T, Allen L, Rowntree L, Kedzierski L, Chua B
Open Forum Infect Dis. 2023; 10(11):ofad550.
PMID: 38023562
PMC: 10644824.
DOI: 10.1093/ofid/ofad550.
COVID-19 Vaccination in Patients With Cancer and Patients Receiving HSCT or CAR-T Therapy: Immune Response, Real-World Effectiveness, and Implications for the Future.
Hall V, Teh B
J Infect Dis. 2023; 228(Suppl 1):S55-S69.
PMID: 37539765
PMC: 10401617.
DOI: 10.1093/infdis/jiad174.
Vaccine schedule recommendations and updates for patients with hematologic malignancy post-hematopoietic cell transplant or CAR T-cell therapy.
Reynolds G, Hall V, Teh B
Transpl Infect Dis. 2023; 25 Suppl 1:e14109.
PMID: 37515788
PMC: 10909447.
DOI: 10.1111/tid.14109.
Safety and immunogenicity of a third dose of mRNA-1273 vaccine among cancer patients.
Giuliano A, Kuter B, Pilon-Thomas S, Whiting J, Mo Q, Leav B
Cancer Commun (Lond). 2023; 43(7):749-764.
PMID: 37377402
PMC: 10354405.
DOI: 10.1002/cac2.12453.
A Three-Dose mRNA COVID-19 Vaccine Regime Produces Both Suitable Immunogenicity and Satisfactory Efficacy in Patients with Solid Cancers.
Janzic U, Bidovec-Stojkovic U, Korosec P, Mohorcic K, Mrak L, Caks M
Vaccines (Basel). 2023; 11(6).
PMID: 37376406
PMC: 10301109.
DOI: 10.3390/vaccines11061017.
COVID-19 infection among patients with cancer in Australia from 2020 to 2022: a national multicentre cohort study.
Hall V, Sim B, Lim C, Hocking C, Teo T, Runnegar N
Lancet Reg Health West Pac. 2023; :100824.
PMID: 37360862
PMC: 10278158.
DOI: 10.1016/j.lanwpc.2023.100824.
Adult Patients with Cancer Have Impaired Humoral Responses to Complete and Booster COVID-19 Vaccination, Especially Those with Hematologic Cancer on Active Treatment: A Systematic Review and Meta-Analysis.
Liatsou E, Ntanasis-Stathopoulos I, Lykos S, Ntanasis-Stathopoulos A, Gavriatopoulou M, Psaltopoulou T
Cancers (Basel). 2023; 15(8).
PMID: 37190194
PMC: 10136728.
DOI: 10.3390/cancers15082266.
The National COVID Cancer Antibody Survey: a hyper-accelerated study proof of principle for cancer research.
Fittall M, Liu J, Platt J, Ionescu M, Sheehan R, Johal S
Br J Cancer. 2023; 128(11):1977-1980.
PMID: 37081188
PMC: 10118226.
DOI: 10.1038/s41416-023-02251-9.
SARS-CoV-2-Specific T Cell Responses in Immunocompromised Individuals with Cancer, HIV or Solid Organ Transplants.
Reeg D, Hofmann M, Neumann-Haefelin C, Thimme R, Luxenburger H
Pathogens. 2023; 12(2).
PMID: 36839516
PMC: 9966413.
DOI: 10.3390/pathogens12020244.
Breakthrough SARS-CoV-2 infections among patients with cancer following two and three doses of COVID-19 mRNA vaccines: a retrospective observational study from the COVID-19 and Cancer Consortium.
Choueiri T, Labaki C, Bakouny Z, Hsu C, Schmidt A, de Lima Lopes Jr G
Lancet Reg Health Am. 2023; 19:100445.
PMID: 36818595
PMC: 9925160.
DOI: 10.1016/j.lana.2023.100445.
Selective suppression of de novo SARS-CoV-2 vaccine antibody responses in patients with cancer on B cell-targeted therapy.
Azar J, Evans J, Sikorski M, Chakravarthy K, McKenney S, Carmody I
JCI Insight. 2023; 8(6).
PMID: 36749632
PMC: 10070099.
DOI: 10.1172/jci.insight.163434.
The Scottish COVID Cancer Immunity Prevalence Study: A Longitudinal Study of SARS-CoV-2 Immune Response in Patients Receiving Anti-Cancer Treatment.
Purshouse K, Thomson J, Vallet M, Alexander L, Bonisteel I, Brennan M
Oncologist. 2023; 28(3):e145-e155.
PMID: 36719033
PMC: 10020811.
DOI: 10.1093/oncolo/oyac257.
Dynamic changes in peripheral lymphocytes and antibody response following a third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients.
Ruggeri E, Nelli F, Giannarelli D, Fabbri A, Giron Berrios J, Virtuoso A
Sci Rep. 2022; 12(1):21908.
PMID: 36535985
PMC: 9761743.
DOI: 10.1038/s41598-022-25558-8.
Efficacy of COVID-19 Booster Vaccines in Patients with Hematologic Malignancies: Experiences in a Real-World Scenario.
Krekeler C, Reitnauer L, Bacher U, Khandanpour C, Steger L, Boeckel G
Cancers (Basel). 2022; 14(22).
PMID: 36428605
PMC: 9688056.
DOI: 10.3390/cancers14225512.
Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer.
Fendler A, Shepherd S, Au L, Wu M, Harvey R, Wilkinson K
Cell Rep Med. 2022; 3(10):100781.
PMID: 36240755
PMC: 9513326.
DOI: 10.1016/j.xcrm.2022.100781.
Antibody response to a third booster dose of SARS-CoV-2 vaccination in adults with haematological and solid cancer: a systematic review.
Al Hajji Y, Taylor H, Starkey T, Lee L, Tilby M
Br J Cancer. 2022; 127(10):1827-1836.
PMID: 36224402
PMC: 9555704.
DOI: 10.1038/s41416-022-01951-y.
